P3 Health Partners Inc. Announces Executive Changes

Ticker: PIIIW · Form: 8-K · Filed: Aug 29, 2024 · CIK: 1832511

P3 Health Partners Inc. 8-K Filing Summary
FieldDetail
CompanyP3 Health Partners Inc. (PIIIW)
Form Type8-K
Filed DateAug 29, 2024
Risk Levelmedium
Pages5
Reading Time6 min
Key Dollar Amounts$0.0001, $11.50, $440,000
Sentimentneutral

Sentiment: neutral

Topics: executive-changes, officer-appointment, director-departure

TL;DR

P3 Health Partners Inc. swapped a director and named a new CMO, with executive pay details also disclosed.

AI Summary

On August 29, 2024, P3 Health Partners Inc. filed an 8-K detailing the departure of Director Dr. Michael L. Riff and the appointment of Dr. David M. Smith as Chief Medical Officer. The filing also addresses compensatory arrangements for certain officers.

Why It Matters

Changes in key leadership roles and executive compensation can signal shifts in company strategy or financial health, impacting investor confidence.

Risk Assessment

Risk Level: medium — Executive changes and compensation disclosures can sometimes precede or indicate underlying business challenges or strategic shifts.

Key Players & Entities

  • P3 Health Partners Inc. (company) — Registrant
  • Dr. Michael L. Riff (person) — Departing Director
  • Dr. David M. Smith (person) — Appointed Chief Medical Officer
  • August 29, 2024 (date) — Date of Report

FAQ

Who has departed from the board of directors at P3 Health Partners Inc.?

Dr. Michael L. Riff has departed from the board of directors.

Who has been appointed as the new Chief Medical Officer?

Dr. David M. Smith has been appointed as the new Chief Medical Officer.

What is the exact date of this 8-K filing?

The exact date of this 8-K filing is August 29, 2024.

What is the principal executive office address for P3 Health Partners Inc.?

The principal executive office address is 2370 Corporate Circle Suite 300 Henderson, Nevada 89074.

What other items are covered in this 8-K filing besides director departure and officer appointment?

This 8-K filing also covers the election of directors and compensatory arrangements of certain officers.

Filing Stats: 1,400 words · 6 min read · ~5 pages · Grade level 12.1 · Accepted 2024-08-29 16:05:55

Key Financial Figures

  • $0.0001 — stered Class A common stock, par value $0.0001 per share PIII The Nasdaq Stock Market
  • $11.50 — A common stock at an exercise price of $11.50 PIIIW The Nasdaq Stock Market LLC Ind
  • $440,000 — w. The Offer Letter provides for (i) a $440,000 annual base salary and (ii) eligibility

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. P3 Health Partners Inc. Date: August 29, 2024 By: /s/ Aric Coffman, M.D. Aric Coffman, M.D. Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.